What Renew Biotechnologies does

Renew Biotechnologies, founded in 2022 and headquartered in Provo, Utah, develops diagnostic and translational research solutions built on its proprietary NESSI-Seq native-read sequencing platform, which leverages Oxford Nanopore long-read technology to simultaneously detect DNA sequence, methylation, and hydroxymethylation patterns without bisulfite conversion or PCR amplification biases. The portfolio includes three commercial products — NeuroLens (a blood-based liquid biopsy for detecting neuron- and glia-derived cfDNA signals linked to active neurodegeneration in Alzheimer's, Parkinson's, and ALS), RNA Clarity (a native RNA sequencing workflow for RNA therapeutic characterization, QC, and lot release), and MethylMap (native-read methylation sequencing for translational methylation programs) — alongside a service catalogue spanning whole-genome, whole methylome, cfDNA methylation, targeted methylation, direct RNA, cDNA, and telomere sequencing, delivered through a 20,000-square-foot CAP/CLIA-certified Renew Labs facility with a custom in-house LIMS. The company also operates a wholly-owned subsidiary, Resonant, focused on neurodegenerative disease blood testing, and serves as the clinical testing provider for Path Fertility's NOA Guide epigenetic diagnostic for non-obstructive azoospermia.

The business operates a hybrid revenue model: professional-services revenue from CAP/CLIA clinical testing and end-to-end sequencing projects, supplemented by product/kits and reagents sales (NeuroLens, RNA Clarity, MethylMap). Pricing is fully quote-based and project-specific with no published tiers, and the company sells through a hybrid direct enterprise sales motion and channel partners, most notably Boston Heart Diagnostics for NeuroLens distribution and Valinor Discovery as an exclusive AI co-development partner authorized to train predictive models on jointly-owned neurological multi-omics datasets. Customers are segmented horizontally across biopharma and drug development companies, academic and clinical research institutions, healthcare providers and clinical laboratories, and fertility clinics, with sales cycles supported by content marketing, scientific publications, conference presentations, and website-driven partnership inquiries.

Strategically, the company is executing an offensive expansion rather than a defensive pivot: it has added new product lines (proteomics "available soon"), a new clinical vertical (reproductive health via Path Fertility), a new brand (Resonant) targeting neurodegeneration, a core technology partnership with Oxford Nanopore, supporting technology integrations with Agilent and Twist Bioscience, academic validation collaborations with BYU and the University of Kansas Alzheimer's Disease Research Center, and an exclusive data/AI partnership with Valinor Discovery — collectively pointing to a coordinated push to translate proprietary native-read sequencing into both clinical diagnostics and data-anchored biopharma services.

Name

Renew Biotechnologies

Legal name

Renew Biotechnologies

Website

https://renewbt.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Renew Biotechnologies develops native-read and long-read sequencing-based diagnostic products and services, including NeuroLens (neurodegeneration liquid biopsy), RNA Clarity, and MethylMap, serving biopharma, academic researchers, and clinical laboratories through a CAP/CLIA-certified lab.

Ownership category

akta.pro rank

Product category

Genomic Sequencing & Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Epigenomics & Chromatin Profiling Services (HLAGANAF), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

Keywords

• Genomic sequencing services
• Epigenetic diagnostics
• Liquid biopsy testing
• Native-read methylation
• Clinical laboratory services

Headquarters

HQ city

Provo

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Clinical Testing Services: CAP/CLIA certified laboratory services providing clinical-grade genomic and epigenetic analysis for diagnostic and monitoring applications, including NeuroLens neuron cell-death testing and Path Fertility NOA Guide diagnostic services.
2. Sequencing Services: End-to-end sequencing services supporting genomic, epigenomic, and transcriptomic analysis from experimental design through bioinformatics and data delivery. Includes direct whole methylome sequencing, whole genome sequencing, direct RNA sequencing, and cDNA sequencing.
3. Products: Sale of proprietary kits and reagents including NeuroLens (neuron cell-death test), RNA Clarity (RNA vaccine QC), and MethylMap (methylation sequencing) products for customer use in their own laboratories.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Renew Biotechnologies develops and delivers clinical diagnostic products and sequencing services built on its proprietary native-read and long-read sequencing platform (NESSI-Seq / Direct Whole Methylome Sequencing). The company sells diagnostic products such as NeuroLens (blood-based liquid biopsy for neurodegeneration) and RNA Clarity (RNA therapeutic QC), and offers end-to-end methylation, whole-genome, RNA, cfDNA, and telomere sequencing services from its CAP/CLIA-certified Renew Labs facility.

Product overview

Renew Biotechnologies offers an integrated platform of clinical diagnostic products and sequencing services powered by proprietary native-read and long-read sequencing technologies. The core product portfolio includes three main offerings: NeuroLens® (blood-based liquid biopsy for neurodegeneration detection), RNA Clarity™ (RNA vaccine QC), and MethylMap™ (native-read methylation sequencing). These clinical products are complemented by a comprehensive suite of sequencing services spanning genomic, epigenomic, and transcriptomic analysis, including Direct Whole Methylome Sequencing, Direct RNA Sequencing, cDNA Sequencing, Whole Genome Sequencing, and Telomere Sequencing. The integrated technology model combines proprietary sequencing workflows with CAP/CLIA laboratory infrastructure to transform molecular signals into clinical and research applications.

Differentiator

Problem solved

Functional benefit

Brands

• NeuroLens®: Blood-based liquid biopsy test for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration
• RNA Clarity™
• MethylMap™
• Resonant
• Renew Labs

Products and services

• NeuroLens® Blood-based liquid biopsy test for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration, enabling early detection and monitoring of Alzheimer's, Parkinson's, and ALS. For biopharma, healthcare providers, and clinical laboratories.
• RNA Clarity™ Native RNA sequencing workflow for multi-attribute RNA therapeutic characterization, quality control, and lot release testing, preserving RNA modifications without reverse transcription artifacts. For RNA therapeutic developers and manufacturers.
• MethylMap™ Native-read methylation sequencing product enabling broader epigenetic coverage and higher-fidelity methylation profiling compared to traditional bisulfite or array methods, for translational methylation programs.
• Direct Whole Methylome Sequencing (gDNA) End-to-end sequencing service for genome-wide methylation analysis using native-read technology that captures sequence, methylation, and hydroxymethylation signals simultaneously, covering up to 98% of the 28.1 million CpG methylation sites.
• Direct Methylation Sequencing (cfDNA) Specialized sequencing service for analyzing cell-free DNA methylation patterns, enabling liquid biopsy applications and non-invasive biomarker detection.
• Direct Targeted Methylation Sequencing (gDNA) Hybrid capture-based long-read sequencing service combining Agilent SureSelect enrichment with native Oxford Nanopore sequencing for integrated analysis of genetic variation and DNA methylation in defined genomic regions.
• Whole Genome Sequencing Comprehensive genomic sequencing service covering the entire genome for variant detection, structural analysis, and comprehensive genomic profiling.
• Direct RNA Sequencing Native RNA sequencing that captures full-length polyadenylated RNA transcripts without reverse transcription or cDNA synthesis, preserving epigenetic modifications and providing accurate long-read sequencing.
• cDNA Sequencing Long-read cDNA sequencing service for transcriptomic analysis, capturing full-length isoforms and complex splicing patterns for biomarker discovery and cancer research.
• Telomere Sequencing Specialized sequencing service for telomere length estimation and analysis, supporting research at the intersection of aging, cancer, and neurodegeneration.

Quantifiable outcome

• 97.6% AUC for Alzheimer's disease discrimination in multi-disease cohorts
• +7 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• Valinor DiscoverycoreStrategic or Co-development Partner · 24 February 2026Strategic collaboration to generate the largest clinical multi-omics dataset for neurological disorders including Alzheimer's, Parkinson's, and ALS. Renew provides clinical laboratory infrastructure and multi-omics data generation capabilities; Valinor provides proprietary machine learning architectures for predictive model development. Companies jointly own resulting datasets with Valinor as exclusive AI partner authorized to train foundation models for biopharmaceutical customers.
• Path FertilitysupportingStrategic or Co-development Partner · 29 January 2026Renew serves as the clinical testing provider for Path Fertility's NOA Guide, an epigenetic diagnostic test for male infertility. The test leverages Renew's native-read sequencing technology to detect sperm-derived cell-free DNA in seminal samples for surgical decision-making in men with non-obstructive azoospermia.
• Oxford Nanopore TechnologiescoreTechnology or Integration · 20 January 2025Collaboration to develop and launch Direct Whole Methylome Sequencing (dWMS) product. The partnership combines Oxford Nanopore's rapid, accessible sequencing technology with Renew's proprietary methylation assays to overcome limitations of traditional bisulfite sequencing and methylation microarrays. Aims to redefine standards in epigenetic research and clinical applications.
• Agilent TechnologiessupportingTechnology or IntegrationDirect Targeted Methylation Sequencing (dTMS) products and services combine Agilent SureSelect enrichment with Renew's native-read workflow for targeted genetic and epigenetic analysis in defined genomic regions.
• Twist BiosciencesupportingTechnology or IntegrationCustom hybridization panels developed with Twist support Oxford Nanopore-based long-read targeted sequencing for complex genomic regions and application-specific targets.
• Boston Heart DiagnosticssupportingChannel Partner/ Reseller/ DistributorStrategic distribution relationship supports NeuroLens products and direct methylation sequencing services for blood-based brain cell death testing, extending Renew's market reach for its neurodegenerative disease diagnostic products.
• Brigham Young UniversitysupportingStrategic or Co-development PartnerResearch collaboration with BYU researchers for validation studies of blood tests for early Alzheimer's disease detection. BYU Life Sciences team leads validation study in collaboration with University of Kansas Alzheimer's Disease Research Center.
• University of Kansas Alzheimer's Disease Research CentersupportingStrategic or Co-development PartnerCollaborative validation study for early Alzheimer's disease detection blood test, working with BYU researchers to conduct clinical validation and advance toward earlier detection, disease progression monitoring, and foundation for new diagnostic tools.

Scale indicators1 record

Recent moves5 records

Expansion highlights6 records

Direct peers

• Oxford Nanopore Technologies: Core technology platform partner and direct player in long-read sequencing. Both companies commercialize Oxford Nanopore-based workflows for methylation and native-read applications targeting biopharma and research customers, making them the closest direct comparable.
• Pacific Biosciences: Long-read sequencing platform competitor with HiFi technology used for methylation detection, structural variant analysis, and translational research. Overlaps directly with Renew's whole-genome, epigenomic, and complex-region sequencing services.
• Element Biosciences: Sequencing platform competitor offering short-read and AVITI systems, with growing presence in epigenomic and translational applications. Comparable to Renew as a sequencing technology company targeting similar research and clinical research customers.
• Natera: Leader in cell-free DNA-based diagnostics, including oncology and reproductive health. Overlaps with Renew's cfDNA methylation work (NeuroLens) and Path Fertility NOA Guide partnership, and both operate CLIA-certified clinical labs.
• Guardant Health: Liquid biopsy and cfDNA analytics company focused on oncology. Comparable to Renew in applying methylation and cfDNA analytics to clinical diagnostics, and operates a similar CAP/CLIA laboratory model serving biopharma and providers.

Broad incumbents

• QIAGEN: Established molecular diagnostics and sample-preparation company with broad methylation, liquid biopsy, and NGS-adjacent product portfolios. Comparable to Renew as a sample-to-insight provider, but operates at a much larger scale and across many more indications.
• Exact Sciences: Major molecular diagnostics company (Cologuard, Oncotype DX) with growing presence in methylation-based liquid biopsy. Comparable to Renew in commercializing methylation biomarkers for clinical use, but at a far more mature commercial stage.
• NeoGenomics: Clinical molecular diagnostics laboratory offering oncology-focused sequencing and methylation services. Comparable to Renew as a CAP/CLIA-certified lab serving biopharma and clinical customers with genomic and epigenomic testing.

Emerging players

• 10x Genomics: Single-cell and spatial genomics platform with adjacency to long-read and multi-omic workflows. Comparable to Renew as a developer of differentiated genomics tools targeting translational and clinical research customers.
• Singlera Genomics: cfDNA methylation-based diagnostics company focused on early cancer detection. Directly comparable to Renew in applying methylation signatures to liquid biopsy for non-invasive disease detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/renew-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renew Biotechnologies